Unknown

Dataset Information

0

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.


ABSTRACT: Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 mutations and mutations in other homologous recombination DNA repair genes is uncertain.Using targeted capture and massively parallel genomic sequencing, we assessed 390 ovarian carcinomas for germline and somatic loss-of-function mutations in 30 genes, including BRCA1, BRCA2, and 11 other genes in the homologous recombination pathway.Thirty-one percent of ovarian carcinomas had a deleterious germline (24%) and/or somatic (9%) mutation in one or more of the 13 homologous recombination genes: BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, and RAD51D. Nonserous ovarian carcinomas had similar rates of homologous recombination mutations to serous carcinomas (28% vs. 31%, P = 0.6), including clear cell, endometrioid, and carcinosarcoma. The presence of germline and somatic homologous recombination mutations was highly predictive of primary platinum sensitivity (P = 0.0002) and improved overall survival (P = 0.0006), with a median overall survival of 66 months in germline homologous recombination mutation carriers, 59 months in cases with a somatic homologous recombination mutation, and 41 months for cases without a homologous recombination mutation.Germline or somatic mutations in homologous recombination genes are present in almost one third of ovarian carcinomas, including both serous and nonserous histologies. Somatic BRCA1/2 mutations and mutations in other homologous recombination genes have a similar positive impact on overall survival and platinum responsiveness as germline BRCA1/2 mutations. The similar rate of homologous recombination mutations in nonserous carcinomas supports their inclusion in PARP inhibitor clinical trials.

SUBMITTER: Pennington KP 

PROVIDER: S-EPMC3944197 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Pennington Kathryn P KP   Walsh Tom T   Harrell Maria I MI   Lee Ming K MK   Pennil Christopher C CC   Rendi Mara H MH   Thornton Anne A   Norquist Barbara M BM   Casadei Silvia S   Nord Alexander S AS   Agnew Kathy J KJ   Pritchard Colin C CC   Scroggins Sheena S   Garcia Rochelle L RL   King Mary-Claire MC   Swisher Elizabeth M EM  

Clinical cancer research : an official journal of the American Association for Cancer Research 20131115 3


<h4>Purpose</h4>Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 mutations and mutations in other homologous recombination DNA repair genes is uncertain.<h4>Experimental design</h4>Using targeted capture and massively parallel genomic sequencing, we assessed 390 ovarian carcinomas for germline and somatic loss-of-function mutations in 30 genes, including BRCA1, BRCA2, and 11 other genes in the ho  ...[more]

Similar Datasets

| S-EPMC4653021 | biostudies-other
| S-EPMC5653668 | biostudies-literature
| S-EPMC7103005 | biostudies-literature
| S-EPMC4550178 | biostudies-literature
| S-EPMC3835434 | biostudies-other